Hepatocellular carcinoma is often diagnosed at an advanced stage, when it is not amenable to curative therapies. There is no effective chemotherapy. Advances in cancer biology suggest that a limited number of pathways are responsible for initiating and maintaining dysregulated cell proliferation, which is the major cellular alteration responsible for the cancer phenotype. New treatments in development target several of these critical pathways, including agents targeting the receptor tyrosine kinase pathways, the Wnt/b-catenin signaling pathway, the ubiquitin/proteasome degradation pathway, the epigenetic DNA methylation and histone deacetylation pathways, the PI3 kinase/AKT/ mTOR pathway, angiogenic pathways, and telomerase. Several of these approaches hold significant promise for improving the long-term outcome of patients with advanced hepatocellular carcinoma. Because of the high prevalence of liver cirrhosis in hepatocellular carcinoma patients, these approaches must be coupled with new strategies for halting or reversing the progression of chronic liver disease.
OVERVIEW Hepatocellular carcinoma (HCC) is the third most important cause of cancer death worldwide, causing an estimated 600,000 deaths in 2002. 1 Only a minority of HCCs are detected at an early enough stage for potentially curative therapies such as surgical resection or liver transplantation. In many liver cancer referral centers, as many as 15 to 25% of patients seen with HCC may be eligible for curative therapy, but on a population basis the percentage is significantly lower, 12% in an analysis of the U.S. Surveillance, Epidemiology, and End Results (SEER) registry from 1998 to 2000. 2 The individuals not eligible for curative therapy are generally treated with local ablative methods such as radiofrequency ablation or alcohol ablation if they have early disease or with transarterial chemoembolization or radioembolization if they have intermediate-advanced disease. 3 There is currently no reliably effective therapy for patients with advanced or metastatic disease. Several agents have been evaluated in clinical trials for therapy of HCC. These include standard chemotherapeutic agents such as doxorubicin, cisplatin, and 5-fluorouracil; hormonal agents such as tamoxifen, megestrol, somatostatin, and statin analogues; and immune modulators such as interferon and a-thymosin. These agents have been tried either individually or in combination. None of these agents or combinations have been shown to have significant efficacy in large randomized trials, although there are many anecdotal reports of efficacy in small series of patients. [4] [5] [6] [7] [8] The current default standard for comparison of new agents is doxorubicin, which has a reported response rate of only 10 to 20% for treatment of HCC, with no effect on survival. 7, 9, 10 Even with combination chemotherapy, any responses observed are typically partial and temporary and the long-term survival of patients with advanced HCC is poor, with a 1-year survival of 17 to 44% and 3-year survival of 8 to 17%. 2, 4, 6, 8 The management of advanced HCC is usually complicated by the presence of underlying liver disease with cirrhosis, portal hypertension, splenomegaly, and pancytopenias as well as active hepatitis or impaired liver synthetic function, or both. The severity of underlying liver disease frequently limits the candidacy of patients for surgical resection and also significantly limits tolerance of chemotherapeutic regimens and access to trials of new chemotherapeutic agents.
Up until now, most therapeutic agents have been developed essentially by trial-and-error testing of large numbers of compounds on in vitro cultured cells, transplantable rodent tumor models, or nude mouse xenografts derived from human cancer cell lines. Most agents identified in these screens have been nonselective cytotoxic agents with significant toxicities to organs with physiologically high rates of proliferation. With advances in our understanding of the molecular pathways regulating oncogenesis, attention has shifted to the development of novel therapeutics targeted against the critical receptors and signaling molecules involved in maintenance of the tumor phenotype. We discuss current concepts of oncogenesis and review the key genes and pathways involved in hepatocarcinogenesis. This discussion is followed by a review of new targeted agents that are in advanced preclinical or clinical development and that are promising therapeutically for HCC.
Cancer Biology
In the last several years there have been important gains in our understanding of the pathogenesis of HCC and our appreciation of the critical oncogenic and tumor suppressor pathways involved in hepatocarcinogenesis. 11 There have also been significant advances in our understanding of fundamental concepts of oncogenesis. Perhaps most important is the growing appreciation of the critical role of unrestricted cellular proliferation in the process of carcinogenesis. Cancers have a complex phenotype that suggests the acquisition of multiple sequential genetic and epigenetic alterations during carcinogenesis. Currently, the dominant paradigm suggests that carcinogenesis occurs through a multistep process resulting in the progression of normal cells through preneoplastic states into invasive cancers. The presumption is that eventually accumulation of a critical combination of alterations in a distinct set of pathways becomes sufficient to deregulate the normal homeostatic mechanisms that regulate cell growth and the cancer phenotype.
The key phenotypic characteristics of cancer cells are self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. It has been proposed that the acquisition of each of these phenotypic characteristics is necessary for the eventual development of the full neoplastic phenotype. 12 Although there is substantial evidence to support this view, it is also becoming increasingly clear that the predominant cellular event necessary for the development of cancer is unconstrained cell proliferation. This depends on the balance between the activity of cell growth and apoptotic signaling pathways, which are interdependent. Consequently, many oncogenic molecules that promote cell proliferation also induce apoptosis, so that they have the homeostatic capability to limit their own proliferative effects. Disruption of this innate homeostatic mechanism by inhibition of the proapoptotic programs normally induced by oncogenic molecules may be the critical second hit that allows unregulated proliferation (Fig. 1) . 13 This ''cancer platform'' concept suggests that the key event driving carcinogenesis is the simultaneous development of deregulated proliferation and reduced cell death; the subsequent development of the additional phenotypes of invasion, angiogenesis, metastasis, and immune evasion are secondary to the development of unrestricted proliferation. Potentially, when an oncogenic signal is coupled with a sufficiently active antiapoptotic signal to drive unregulated proliferation, the additional phenotypic changes of cancer arise through interactions of the proliferating cell mass with the surrounding tumor microenvironment. The redundancy of the proliferative and proapoptotic biological networks means that disruption of a particular protein leads to effects that may not directly reflect the normal function of the protein but may be the net result of the altered balance between its activity and the activity of opposing signals within the network. 14 The concept of ''intrinsic tumor suppression'' proposed by Lowe et al suggests that the uncontrolled cell proliferation that is key to the cancer phenotype is a consequence of the suppression of innate tumor suppressive mechanisms that couple oncogene activation to apoptosis or cellular senescence. These tumor suppressive mechanisms depend on a complex network of apoptosis and cell cycle regulators, including p53, p63, p73, p16, ARF, p21
, pRb, and multiple Bcl2 family proteins.
These concepts are important because they inform our view of the potential importance of a single or a few molecular events in the carcinogenic process. If the molecular event results in a substantial enhancement of an oncogenic or antiapoptotic signal, it may have a profound influence on the susceptibility of the liver to carcinogenesis. Because of the presence of a complex network of molecules within both the oncogenic and antiapoptotic programs, genetic or epigenetic alterations may affect different molecules but have similar results on the overall cellular phenotype. A typical example of the interaction between pathogenic mechanisms in the development of HCC is illustrated by the synergism between dietary aflatoxin intake and chronic hepatitis B virus (HBV) infection in carcinogenesis. Aflatoxin exposure results in p53 mutations, most commonly at codon 249. Wild-type p53 promotes apoptosis and is induced by many oncogenes in a negative feedback loop to limit proliferation. Inactivation of p53 by mutation severely compromises oncogene-induced apoptosis and also leads to defects in DNA damage checkpoints and to gross aneuploidy. 15 Consequently, aflatoxin-induced p53 mutations may render hepatocytes highly susceptible to the effects of HBV infections that activate oncogenic pathways and may also predispose to the development of aneuploid HCCs with a more aggressive phenotype. Besides deregulated cell growth, perhaps the only additional cancer phenotype for which there is strong evidence for the involvement of specific genes and pathways is the ability of cancer cells to metastasize. 16 However, even for the metastatic phenotype, there is evidence of overlap of the regulatory pathways with pathways that control cell proliferation. For example, experiments with a newly developed mouse model of HCC induced by the mouse polyoma virus middle T antigen (PyMT) showed that loss of p53 cooperates with specific PyMT functions to mediate the formation of poorly differentiated, invasive, and metastatic tumors. 17 This view of the need for relatively few critical alterations for the maintenance of the carcinogenic state also predicts that individual cancers may have a limited number of critical pathways that can be targeted to inhibit growth or reactivate the normal pathways of oncogene-induced apoptosis. Initial evidence to support this hypothesis comes from studies showing the impact of the tyrosine kinase inhibitor imatinib (Gleevec) on gastrointestinal stromal tumors dependent on activating mutations in the transmembrane receptor of stem cell growth factor, c-kit, and platelet-derived growth factor (PDGF) receptor for their growth, 18, 19 as well as studies showing the impact of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (Iressa) on the subgroup of non-small cell lung cancers with particular activating somatic mutations in the EGFR coding region. 20, 21 Cure of a case of advanced liver cancer after treatment with imatinib has been reported. 22 It has been hypothesized that some liver cancers arise through malignant transformation of the somatic stem cells of the liver, called oval cells. Oval cells are c-kit-positive cells located among the biliary cells of the canal of Hering. The expression of c-kit on oval cellderived cancer cells may be the mechanism for efficacy of imatinib in this case and may define a subgroup of HCCs sensitive to this agent.
More dramatic preclinical evidence for the potential for targeted treatment of HCCs by interfering with critical oncogenic pathways comes from the work of Shachaf et al, who have shown that HCCs developing in transgenic mice that conditionally express the Myc oncogene in a liver cell-specific manner regress completely when Myc expression is inactivated by treating the mice with doxycycline. 23 After Myc inactivation and tumor regression, a subpopulation of the tumor cells remain which differentiate into hepatocytes and biliary cells. These differentiated cells remain capable of regenerating tumors when Myc expression is reactivated by withdrawal of doxycycline, suggesting that abrogation of Myc expression places this subpopulation of malignant cells in a state of dormancy. This series of experiments is a powerful demonstration of the effects of perturbation of a single pathway on the oncogenic process and also reinforces the cancer platform concept that the key phenotype necessary for the development of cancer is unregulated cell proliferation.
Another important emerging concept in carcinogenesis comes from observations that not all the cells in a cancer are capable of self-renewal and maintenance of tumor growth. Recent evidence suggests that most tissues contain a subpopulation of stem cells that is capable of self-renewal and that gives rise to the bulk of the tissue cells. The size of this population of cells is normally tightly regulated. Cancer may result from a loss of regulation of this stem cell compartment, leading to unrestrained proliferation of the tissue. 24 The tumor stem cell compartment has different cell surface markers and gene expression signatures and may be responsive to different therapeutic agents than the bulk of the tumor cells, which are partially differentiated from the stem cell phenotype. In the inducible Myc model of mouse HCC described earlier, the subpopulation of tumor cells that differentiates into hepatocytes and biliary cells upon Myc inactivation but remains capable of regenerating tumors when Myc is reexpressed may represent the selfrenewing tumor stem cell compartment. The important implication of this concept for cancer therapy is that to treat a cancer effectively, it will be critical to understand the genes and pathways that regulate unconstrained proliferation of the tumor stem cell compartment; conversely, agents that induce apoptosis or senescence of only the partially differentiated non-stem cell compartment may induce partial remission or stabilization of tumor growth but be unable to cure the cancer.
The majority of HCCs develop in patients with chronic inflammation related to chronic hepatitis B or C virus infection, chronic alcohol abuse, or other causes. Evidence from the Mdr2 knockout mouse model of hepatitis-induced carcinogenesis suggests that infiltrating endothelial and inflammatory cells release tumor necrosis factor a (TNF-a), which acts on nearby hepatocytes by activating nuclear factor kappa B (NFkB). 25 In this model activation of NFkB occurs early but does not appear to be required for the development of preneoplastic initiated foci characterized by high proliferation rate, hyperploidy, and dysplasia. However, beyond the stage of initiation, NFkB activation is critical for promoting tumor progression into an invasive malignant phenotype. NFkB activates antiapoptotic genes such as A1/Bfl1, c-IAP1, and GADD45 b. In addition, TNF-a mediates increased expression of c-Jun and c-jun aminoterminal kinase (JNK), which cooperate to inhibit p53-mediated apoptosis. Inflammation therefore appears initially to promote hepatocyte proliferation and the development of preneoplastic foci through pathways that are not dependent on TNF-a and NFkB; subsequently, antiapoptotic effects mediated by TNF-a are critical for the tumor progression phase of hepatocarcinogenesis. Inactivation of the TNF-a signaling pathway may therefore be an important strategy for chemoprevention of HCC.
PATHWAYS AND TARGETED THERAPIES
In the remainder of this article, we highlight the major cellular signaling mechanisms known to play a role in hepatocarcinogenesis for which targeted agents are currently under development or in clinical trials for modulation of these pathways in the treatment of cancer. The goal of targeted therapy for cancer is to treat the cancer without significant side effects typical of the use of standard chemotherapeutic regimens based on cytotoxic agents, antimetabolites, and so forth. Because these standardized regimens have limited effectiveness in the therapy of solid tumors such as HCC, there is also considerable and critical interest in improving response to therapy. As previously mentioned, the treatment of HCC is frequently complicated by the presence of underlying liver disease as well as by the fact that chronic hepatitis or cirrhosis results in a field defect that predisposes the entire liver to the development of HCC. Consequently, when HCC develops, treatment of the incident tumor without introduction of measures to prevent development of new tumors amounts to simple temporizing. Therefore, there is a critical need not only for surveillance of individuals with cirrhosis to allow early detection and eligibility for more radical therapies but also for the development of therapies for chemoprevention of HCC or for reversal of cirrhosis, or both. Some of the agents or classes of agents described here may turn out also to have utility in secondary chemoprevention of HCC. Although remarkable progress continues to be made in the general areas of gene targeting and therapy and the development of antibody and immune-directed therapies, the target pathways for these agents overlap significantly with the pathways that we review here. Because none of these therapies are imminently ready for clinical use and because of space limitations, we do not review them in detail here.
Receptor Tyrosine Kinase Pathways and Inhibitors
A majority of the agents currently under development for targeted treatment of cancer are directed against the cell membrane receptor tyrosine kinase pathways ( Table 1 ). The Ras mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)-Akt kinase signaling pathways are activated by ligand binding and phosphorylation of several growth factor tyrosine kinase receptors, including the EGF receptors, the fibroblast growth factor (FGF) receptors, the hepatocyte growth factor (HGF) receptor c-met, the stem cell growth factor receptor c-kit, the PDGF receptor, and the vascular endothelial growth factor (VEGF) receptor. The downstream consequences of activation of these receptors are multiple and include activation of the Grb2/Shc/SOS adapter molecule complex and downstream activation of the Ras/Raf/Erk 1/2 MAPK pathway, which results in activation of the AP-1 transcriptional activators c-fos and c-jun and consequent induction of transcription of genes that drive cell proliferation (Fig. 2) . Several compounds currently under investigation inhibit the tyrosine kinase receptor pathways at different levels, including antibodies that bind to the receptors and block ligand-receptor interactions, small molecule inhibitors of the receptor tyrosine kinases, and inhibitors of the downstream activators such as protein kinase C and Raf (Table 1) .
Early clinical studies performed to date in HCC and other cancers have typically shown minimal or limited effectiveness of agents targeted against these pathways, even when the pathways are known to be activated in the specific cancer. This suggests that there is significant redundancy in the signaling pathways that support tumor growth and has led to more sophisticated efforts aimed at targeting multiple molecules and levels in growth factor signaling pathways. Thus, several new agents such as BAY 43-9006 inhibit multiple pathway components, in this case both Raf kinase and VEGF receptor. Initial clinical studies of BAY 43-9006 showed a partial response in a patient with HCC. 26 Additional clinical studies with this agent are under way. Other receptor tyrosine kinase and pathway molecule inhibitors for which preclinical studies relevant to HCC have been published include the EGFR tyrosine kinase inhibitor gefitinib (Iressa) 27 and the PI3K inhibitor FTY720, which suppressed motility of the metastatic H2M HCC cell line by down-regulation of the Rac-GTP level. 28 CI-1040 is an oral inhibitor of mitogenactivated extracellular signal regulated kinase kinase (MEK), a key enzyme in the Ras-Raf-MEK-extracellular signal regulated kinase (ERK) kinase pathway, which is constitutively active in a variety of solid tumors. On the basis of encouraging phase I results, a phase II study was performed in patients with advanced breast cancer, colon cancer, non-small cell lung cancer, and pancreatic cancer. CI-1040 was generally well tolerated but demonstrated insufficient antitumor activity to warrant further development in the four tumors tested. PD 0325901, a second-generation MEK inhibitor, has entered clinical development. It has enhanced pharmacologic and pharmaceutical properties compared with CI-1040 and may realize the therapeutic potential of MEK inhibition in cancer.
The enzyme farnesyl transferase catalyzes the first step in the post-translational modification of several guanine nucleotide-binding proteins (G proteins) involved in cell signaling. Cytoplasmic G protein precursors are converted to mature membrane-bound forms through a series of post-translational modifications, the first of which is protein prenylation, which is the covalent addition of either farnesyl (15 carbon) or geranylgeranyl (20 carbon) groups to a cysteine residue at the COOH terminus of the protein. Prenylation promotes the association of the modified G proteins with various cellular membranes, including the plasma membrane (Ras), peroxisomal membrane (PxF), and nuclear membrane (lamins A and B), and also mediates protein-protein interactions. Ras proteins transduce receptor and nonreceptor tyrosine kinase activation to downstream cytoplasmic and nuclear effectors. Oncogenic Ras mutations have been identified in 30% of human cancers, and these activating mutations result in constitutive signaling, leading to cell proliferation and inhibition of apoptosis. Because farnesylation is critical for maturation and function of Ras, farnesyl transferase inhibitors (FTIs) were developed as potential inhibitors of Ras-mediated cell proliferation. However, it has been shown that FTIs target other polypeptides in addition to Ras, including Rho B, lamins A and B, transducin, the centromeric proteins CENP-E and F, rhodopsin kinase, and other proteins associated with the PI3 kinase/AKT pathway. Several FTIs are in different stages of preclinical and clinical testing, including the methylquinolone R115777. In a phase I trial of the combination of R115777 with gemcitabine and cisplatin in patients with advanced solid tumors, nine objective responses (one complete response and eight partial responses) were Figure 2 The receptor tyrosine kinase signaling pathway.
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documented in 27 patients. 29 Additional agents are under development that target the Ras molecule, including ISIS 2503, an oligodeoxynucleotide antisense inhibitor of H-ras. 30 
Wnt/b-Catenin Pathway and Inhibitors
Wnts are secreted cysteine-rich glycoprotein ligands that act as ligands for the Frizzled family of cell surface receptors and activate receptor-mediated signaling pathways. The best-studied Wnt pathway activates b-catenin, which in turn binds to the T-cell factor (TCF) and lymphoid enhancer binding protein (LEF) family transcription factors, activating transcription of genes regulating cell proliferation and survival. In the absence of Wnt ligands, most cellular b-catenin associates with E-cadherin in adherence junctions at the plasma membrane (Fig. 3) . Cytosolic b-catenin associates in a complex with adenomatous polyposis coli (APC) and AXIN1 or AXIN2, which mediates sequential phosphorylation of b-catenin by casein kinase 1 and glycogen synthase kinase 3 b (GSK3 b). Phosphorylation of b-catenin triggers its ubiquitination by b-transducin repeat-containing protein and subsequent proteosomal degradation. Extracellular Wnt ligands bind to Frizzled family receptors at the cell surface, leading to activation of the intracellular molecule dishevelled and its recruitment to the membrane. Dishevelled in turn has two actions; it recruits AXIN to the plasma membrane, where it is degraded, and it inhibits GSK3 b. Both actions decrease the degradation of b-catenin and increase its cytoplasmic level. Beta-catenin then translocates to the nucleus, interacts with the TCF and LEF transcription factors, and activates the transcription of target genes, including cyclin D1, c-Myc, c-Met, FGF4, metalloproteinases, and VEGF. Gain-of-function mutations in the b-catenin gene and loss-of-function mutations in the APC, AXIN1, or AXIN2 genes activate b-catenin signaling and oncogenesis.
Activation of the Wnt pathway occurs in 30 to 40% of HCCs and is due to mutations in the b-catenin gene in 12 to 26% of human HCCs and to mutations in AXIN1 or AXIN2 in 8 to 13% of human HCCs. 31 Inactivation of APC in mouse liver has been shown to lead to the development of HCCs. 32 Wnts are involved in regulation of liver regeneration and in the maintenance and self-renewal of pluripotent stem cells and progenitor cells; hence, they may play a role in the maintenance of the cancer stem cell compartment and may be ideal targets for cancer therapy. 33, 34 Agents under development for targeting the Wnt pathway in cancer include small molecule inhibitors that block interaction of b-catenin with TCF, such as the fungal derivatives PKF115-854 and CGP049090 35 or interaction of b-catenin with cAMP response element binding protein (CREB) binding protein (CBP), such as the small molecule ICG-001, 36 and therapeutic monoclonal antibodies against Wnts. 37, 38 In addition to agents under development to target the Wnt pathway, several established drugs currently in clinical use have been shown to have activity against the Wnt pathway. 39 These include the nonselective cyclooxygenase (COX) inhibitors indomethacin, 40, 41 sulindac, 42 aspirin, 41 and nitric oxide-releasing aspirin 43 and the selective inhibitors celecoxib and rofecoxib. 44 There is also evidence to suggest that imatinib and endostatin inhibit Wnt signaling. 45, 46 Although the development of targeted therapies against this pathway is still at an early stage, because of the importance of Wnt signaling in HCC, there is strong anticipation that these therapies may prove useful for HCC.
Ubiquitin-Proteasome Pathway and Inhibitors
The ubiquitin-proteasome system is a highly conserved eukaryotic system for cellular protein degradation. Approximately 80% of cellular protein is degraded by the proteasome in the cytoplasm and nucleus after being tagged with ubiquitin. The remaining 20%, mostly cell surface proteins, are taken up by endocytosis and degraded in lysosomes. Ubiquitin-proteasome-mediated protein degradation is accomplished through the ligation of ubiquitin to proteins targeted for degradation through a sequence of steps involving a ubiquitin-activating enzyme (E1) and multiple ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s) (Fig. 4) . The ubiquitin-activating enzyme E1 mediates ATP-dependent transfer of ubiquitin to an E2 ubiquitin-conjugating enzyme. The E2 enzyme subsequently transfers the ubiquitin moiety either directly to the substrate protein or to a downstream E3 ligase that then ubiquitinates its specific substrate or substrates. Sequential addition of ubiquitin molecules to the nascent ubiquitin chain results in the formation of a polyubiquitin chain. Polyubiquitinated proteins are recognized and degraded by the multisubunit 26S proteasome into peptide fragments and ubiquitin monomers, which are then recycled. The proteasome has three different peptidase activities, with trypsin-like, chymotrypsin-like, and caspase-like (peptidylglutamyl-peptide hydrolyzing) activities.
Several cancer-related proteins are regulated by the ubiquitin-proteasome system, including the tumor suppressors p53, p27, pRb, and PTEN; the cell surface tyrosine kinase growth factor receptors EGFR and transforming growth factor b (TGF-b) receptor; and other cell cycle regulators and oncogenic molecules. 47 In addition, several cancer-related proteins have been shown to participate in the ubiquitin conjugation machinery, including mouse double minute 2 (mdm2) and BRCA1, both of which are E3 ligases that target p53 for ubiquitination and degradation 48, 49 ; Smad ubiquitination regulatory factor-2 (Smurf2), an E3 ligase that targets Smad proteins and the TGF-b receptor complex for degradation 50 ; and the FRA6E fragile site protein Parkin, an E3 ligase that targets cyclin E and P38 and has been shown to function as a tumor suppressor in HCC. 51 Several agents have been developed that target the 26S proteasome complex or individual E3 ligases. The first of these compounds to receive Food and Drug Administration approval was bortezomib or PS-341 (Velcade), a dipeptide boronic acid analogue that is a potent, selective, and reversible inhibitor of the 26S proteasome. Because it targets the final common effector Figure 4 The ubiquitin-proteasome pathway.
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in the ubiquitin-proteasome pathway, bortezomib affects multiple proteins. It has been shown to inhibit tumor growth and induce apoptosis of multiple cancer cell types and was approved for the treatment of multiple myeloma. Additional studies with bortezomib are under way in multiple tumor types, including HCC. Several agents targeted against specific E3 ligases, which have the potential for more selective targeting of cancerrelated molecules, are currently in development. A small molecule inhibitor that specifically targets Mdm2 and prevents its interaction with p53, named Nutlin-3, has been described. 52 It is anticipated that multiple additional agents designed to target substrate-specific E3 ligases will be developed to yield a new class of anticancer therapeutics.
Epigenetic Promoter Methylation and Histone Acetylation Pathways and Inhibitors
The major epigenetic modification of DNA is the methylation of cytosine nucleotides that precede guanines to form CpG dinucleotides. Approximately 6 to 8% of all cytosines in normal human DNA are methylated. Cancer cells are characterized by the presence of discrete areas of dense hypermethylation on a background of global hypomethylation. The hypomethylation occurs primarily within repetitive DNA sequences and is thought to contribute to chromosomal instability; in contrast, hypermethylation occurs in CpG islands located in the promoters and regulatory introns of many tumor suppressor genes, including the p16 INK4a , M6P/IGFR2, BRCA1, and E-cadherin genes. Compounds that inhibit DNA methylation lead to demethylation of the CpG islands and reexpression of the tumor suppressors, consequently inhibiting tumor growth. DNA demethylating agents currently approved or under evaluation for treatment of cancer include 5-azacytidine (Vidaza), 5-aza-2'-deoxycytidine (decitabine), zebularine, procainamide, and procaine. Histone deacetylation also causes gene silencing, and pharmacological manipulation of chromatin remodeling by histone deacetylase (HDAC) inhibitors has also been used as a strategy for the treatment of cancer.
HDAC inhibitors include short-chain fatty acids, such as 4-phenylbutyrate and valproic acid; hydroxamic acids, such as suberoylanilide hydroxamic acid, pyroxamide, trichostatin A, oxamflatin, and cyclic hydroxamic acid-containing peptides (CHAPs); cyclic tetrapeptides, such as trapoxin, apicidin, and depsipeptide-also known as FK-228 or FR 901228; and benzamides, such as MS-275. 53, 54 HDAC inhibitors suppress the activities of multiple HDACs, leading to an increase in histone acetylation. Histone acetylation enhances the expression of specific genes that elicit metabolic and morphologic changes in cells including growth arrest, differentiation, and apoptosis. In HCC, studies have reported that sodium butyrate and trichostatin A induce cellular differentiation, suppress growth and tumorigenicity, and induce apoptosis of the HCC cell lines Huh7 and Hep3B. [55] [56] [57] In contrast, it has been shown that sodium butyrate induces cell growth arrest and differentiation but not apoptosis of the human HCC cell lines HCC-M and HCC-T. 58, 59 Apicidin, a novel HDAC inhibitor derived from a fungal metabolite, has been shown to activate transcription of the tumor suppressor p21 WAF1, CIP1 and induce apoptosis of human leukemic cells. [60] [61] [62] [63] A new generation of HDAC inhibitors are in early phase clinical trials, including LAQ824, PDX101, MS-275, and CI-994. Of particular interest is the fact that DNA demethylating agents and HDAC inhibitors have synergistic effects in the reactivation of hypermethylated tumor suppressor genes. 64 Consequently, several studies are under way that explore the use of these two classes of agents in combination.
PI3Kinase/AKT/mTOR Pathway Multiple cellular growth factors, including insulin and insulin-like growth factors and cytokines such as interleukin-2, activate the PI3K family of enzymes, which produce the lipid second messenger phosphoinositol triphosphate (PIP3) and related second messengers. PIP3 in turn activates Akt/protein kinase B (PKB). Activated Akt phosphorylates several cellular target proteins, including the proapoptotic protein BAD, which is inactivated by phosphorylation, and also the mammalian target of rapamycin (mTOR) subfamily of proteins (Fig. 5) . mTOR proteins in turn regulate the phosphorylation of p70 S6 kinase, a serine-threonine kinase, and the translational repressor protein PHAS-1/ 4E-BP. These proteins regulate translation of cell cycle regulatory proteins and promote cell cycle progression. The PTEN tumor suppressor gene product is a lipid phosphatase that inhibits this pathway by reversing the PI3K reaction and blocking Akt activation. Mutation or silencing of the PTEN gene therefore leads to activation of the pathway and promotes carcinogenesis. Rapamycin, a macrolide antibiotic with antifungal and immunosuppressive properties, binds to cytoplasmic FK506-binding protein-12 (FKBP12) and in complex with FKBP12 inhibits the mTOR family kinases. Consequently, rapamycin and other mTOR kinase inhibitors show significant activity against cancers with activated PI3K/Akt pathways. 65 mTOR inhibitors currently in clinical development include RAD001, 66 AP23573, 67 and CCI-779. 68 PTEN expression is reduced or absent in almost half of HCCs, and hepatocyte-specific abrogation of PTEN expression in mice results in the development of HCCs. 69 In a recently reported study, overexpression of phospho-mTOR was found in 15% of HCCs. mTOR phosphorylation was associated with increased expression of total p70 S6 kinase, which was found in 45% of HCCs. In vitro experiments showed that rapamycin reduced p70 S6K phosphorylation and markedly inhibited proliferation of both HepG2 and Hep3B HCC cell lines. 70 These findings suggest a potential utility for mTOR inhibitors in HCC.
Angiogenic Pathways and Inhibitors
Substances produced by cancer cells in response to local hypoxia or the interaction of the proliferating mass of cells with surrounding stromal tissue stimulate the growth of new blood vessels from the surrounding parenchyma into the tumor. Signaling pathways critical to the angiogenic process include growth factormediated pathways such as VEGF and FGF receptor signaling as well as the nitric oxide signaling pathway. Hypoxia induces expression of hypoxia inducible factor 1 (HIF1) and insulin-like growth factor 2 (IGF2), both of which stimulate expression of VEGF and other growth factors (Fig. 6) . [71] [72] [73] There is also evidence to suggest that vasculogenic stem cells may be recruited from the bone marrow during tumorigenesis. HCCs are highly vascular and presumably dependent on active neoangiogenesis for their growth. Consequently, several agents specifically targeting angiogenic pathways have been investigated or are currently under investigation for efficacy in treating HCC, many of which target the VEGF pathway and downstream signaling pathways and are now in clinical trials (Table 1) . These agents presumably have both antiproliferative and antiangiogenic effects. In parallel with the increase in angiogenic stimuli, it has been shown that the expression of collagen XVIII, the precursor of the antiangiogenic molecule endostatin, is decreased in larger and more vascular HCCs. 74 There is preclinical evidence suggesting activity of endostatin against HCC, 75 and several models, including adenovirus-mediated gene transfer, are under investigation for delivery of endostatin to HCCs. 76 Endothelial nitric oxide synthase (eNOS) appears to be involved in regulating the hyperpermeability that is characteristic of the tumor microvasculature. Blockade of eNOS may therefore have antitumor effects. The caveolin 1-derived peptide cavtratin inhibits eNOS and has been shown to block tumor progression in mice. 77 Similar agents may have efficacy as antiangiogenic drugs against human HCC. There have been isolated reports of efficacy of the antiangiogenic drug thalidomide in individual cases of HCC, 78 but a recently completed controlled trial reported significant side effects with no evidence of durable efficacy. 79 Telomerase as a Target Telomeres are specialized protein-DNA structures at the ends of chromosomes that contain long stretches of TTAGGG hexameric repeats. Telomeres prevent degradation of chromosome ends and end-to-end fusion with other chromosomes. Aging of somatic cells is associated with reduction in telomere length because of the inability of traditional DNA polymerases to replicate completely the end of the chromosomal DNA. In contrast, germ line and neoplastic cells express telomerase, Figure 5 The PI3Kinase/AKT/mTOR pathway.
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an enzyme that restores telomere length. There is progressive shortening of telomeres during progression from chronic hepatitis to cirrhosis and eventually to HCC. 80 The shortening occurs as a consequence of the multiple cycles of cell injury, death, and regeneration that occur in chronically inflamed liver, leading to premature hepatocellular senescence. Telomere shortening beyond a critical length leads to a proliferative block referred to as telomeric crisis, which is characterized by chromosomal instability, end-to-end fusions, and cell death. Stabilization of the telomeric DNA through either telomerase activation or the activation of an alternative mechanism of telomere maintenance is essential if the cells are to survive and proliferate indefinitely. 81 There is crosstalk between the oncogene and telomerase pathways, as c-myc has been shown to activate the telomerase gene promoter. 82 Hepatocarcinogenesis is characterized by the evolution of clones of hepatocytes with increased telomerase expression and an immortalized phenotype. 83 Therefore, almost all HCCs show reactivation of telomerase activity. 84 Telomerase is an attractive target for anticancer drug development. Because it is usually not expressed in normal cells, it is likely that there will be no serious side effects from treatments that abrogate telomerase activity. Inhibition of telomerase activity leads to telomere shortening and induces growth arrest and senescence of cancer cells. Inhibition of telomerase also increases the sensitivity of cancer cells to chemotherapy-induced apoptosis, suggesting a role as an adjuvant therapy. Several approaches have been explored for inhibition of telomerase activity; these include the use of antisense agents, small interfering RNAs, or dominant negative mutants targeted to the human telomerase reverse transcriptase gene or the telomerase RNA component. 85 Small molecule inhibitors of the telomerase reverse transcriptase show anticancer activity, but with persistent treatment resistant clones emerge with reactivated telomerase. Tankyrase 1 is a telomeric poly(ADP-ribose) polymerase (PARP) that normally ribosylates telomeric repeat binding factor 1, leading to its degradation and resulting in telomere elongation. PARP inhibitors have been shown to block tankyrase 1 activity, and combination treatment with small molecule PARP inhibitors has been shown to enhance the effect of telomerase inhibitors. 86 These findings suggest a potential utility for inhibition of the telomerase pathway in anticancer therapy.
SUMMARY
With improvements in our understanding of the molecular mechanisms of oncogenesis and advances in the design and development of targeted therapeutics, we are poised at the beginning of a new era of application of targeted therapies for treatment of cancer, and there is reason to be cautiously optimistic that more rational and effective therapies for advanced HCC will become available within the next few years. In addition, the use of targeted therapies will almost certainly be coupled with advances in personalized medicine, so that therapies are designed based on the innate propensities of individuals to metabolize and respond to particular therapeutics and also based on genomic, proteomic, glycomic (related to glycan signaling), kinomic (related to kinase signaling), or other signatures of the tumor that predict response to therapy. In fact, studies have already reported the use of gene expression analysis to predict response to chemotherapy in advanced HCC. 87, 88 The convergence of advances in tumor biology and therapeutic technology gives hope for the eventual development of highly effective therapies against difficult-to-treat solid tumors such as HCC. 
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